
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc. has reported a 41% quarter-over-quarter increase in NeXT Personal Dx volumes for Q4'25, exceeding market expectations and indicating strong momentum for the company's testing solutions. The recent acquisition of Medicare coverage for the NeXT Personal MRD test, particularly in breast cancer, coupled with expected marketing acceleration by commercial partner Tempus, presents significant growth opportunities in the near future. Additionally, the company's focus on distinguishing its tests in early cancer recurrence detection, evidenced by the performance data showing 40% of ctDNA positive samples in the 1-100ppm detection range, underscores the value proposition of its offerings in a rapidly evolving market.
Bears say
Personalis Inc has provided a downward revision of its revenue guidance for 2025, projecting a decrease to $68 million-$73 million from a prior estimate of $70 million-$80 million, which highlights a concerning year-over-year decline in pharmaceutical services revenue partially due to the conclusion of Moderna’s Phase III melanoma trial. Furthermore, the company has encountered logistical challenges affecting its global sample processing, which may hinder its ability to capitalize on market opportunities amidst a general slowdown in the biopharmaceutical sector. Lastly, concerns about significant losses incurred since inception, compounded by existing debt, raise doubts about Personalis’s capacity to achieve long-term profitability and revenue sustainability.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares